ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2019
Update on the management of febrile neutropenia in hematologic patients.
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05133310 (Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia
Who cites it
16 citing papers in PubMed.
- Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Multinational association for supportive care in cancer (MASCC) versus clinical index of stable febrile neutropenia (CISNE): evaluation of predictive performance and clinical utility in patients with febrile neutropenia.European journal of medical research · 2025Article
- Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.BMC cancer · 2025Article
- Utilizing Viral Metagenomics to Characterize Pathogenic and Commensal Viruses in Pediatric Patients with Febrile Neutropenia.Viruses · 2025Article
- The Role of Bronchoalveolar Lavage in Therapeutic Antimicrobial Choices for Hematologic Patients with Pulmonary Infiltrates.Medicina (Kaunas, Lithuania) · 2025Observational
- Causal Relationship Between Gut Microbiota and Leukemia: Future Perspectives.Oncology and therapy · 2024Review
- Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR).JAC-antimicrobial resistance · 2024Review
- Clinical and Microbiological Characteristics of Febrile Neutropenia During Induction Chemotherapy in Adults With Acute Leukemia.Cancer reports (Hoboken, N.J.) · 2024Article
- Anorectal Pathologies in the Course of Acute Leukaemias; Predictive Parameters.Mediterranean journal of hematology and infectious diseases · 2024Article
- Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia.Frontiers in cellular and infection microbiology · 2024Article
- Blood plasma metagenomic next-generation sequencing for identifying pathogens of febrile neutropenia in acute leukemia patients.Scientific reports · 2023Article
- Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy.Microorganisms · 2023Article
- Prevalence of blood stream infections and associated factors among febrile neutropenic cancer patients on chemotherapy at Ocean Road Cancer Institute, Tanzania.Infectious agents and cancer · 2023Article
- The Clinical Characteristics of ARDS in Children With Hematological Neoplasms.Frontiers in pediatrics · 2021Article
- Epidemiology of Febrile Neutropenia Episodes with Gram-Negative Bacteria Infection in Patients Who Have Undergone Chemotherapy for Hematologic Malignancies: A Retrospective Study of 10 Years' Data from a Single Center.Infection and drug resistance · 2020Article
- Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febrile neutropenia is a common complication in patients with hematologic malignancies receiving chemotherapy, and is associated with high morbidity and mortality. Infections caused by multidrug-resistant bacteria represent a therapeutic challenge in this high-risk patient population, since inadequate initial empirical antibiotic treatment can seriously compromise prognosis. Besides, reducing antimicrobial exposure is a cornerstone in the fight against resistance.
Indexed as
Identifiers
31475812PMC6755372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.